Jan A. Alfheim

Jan A. Alfheim

Company: Oncoinvent

Job title: Chief Executive Officer

Seminars:

Phase 1 Development of Radspherin 2:45 pm

Radspherin®, is a new alpha-emitting radioactive microsphere designed for treatment of metastatic cancers in body cavities Radspherin® has in animal models been shown to cause a reduction in tumour cell growth and a significant increased survivalRead more

day: Day 1 Track A

© Copyright 2022 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.